Aplastic anemia drug combo study pulled before starting
NCT ID NCT07523009
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study was designed to test whether combining cyclosporine with drugs that boost platelet production (eltrombopag, hetrombopag, or romiplostim) could help people with newly diagnosed severe aplastic anemia who need blood transfusions. The trial was withdrawn before enrolling any participants, so no results are available.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Cyclosporine, eltrombopag, hetrombopag, and romiplostim
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SEVERE APLASTIC ANEMIA (SAA) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Experimental drug targets bone marrow failure
- Simpler stem cell collection could ease donor burden in Life-Threatening anemia
- New drug cocktail aims to free aplastic anemia patients from transfusions
- New hope for aplastic anemia: drug combo aims to cut transfusions
- Promising combo for aplastic anemia trial pulled before start
- New drug combo shows promise for rare blood disorder